Santhera has provided an update to the Duchenne community, which contains updates on the SIDEROS study, educational events, respiratory guidelines/care, and more. Click here to view the update.
Study of whether idebenone is safe and effective at delaying the loss of respiratory function
The SIDEROS clinical trial is currently recruiting boys with DMD ages 10 and older at 24 trial sites in the U.S. The study will compare the efficacy of idebenone to placebo in boys and men currently on steroids. Idebenone is an investigational drug in Phase 3 development for patients with DMD who are in respiratory decline.
To be eligible for the trial, boys must be: 10 or older; immunized against the flu and pneumonia; have a FVC of between 35-80% predicted; and be on steroids for at least 12 months with no dose adjustments in the last 6 months (can switch between prednisone and deflazacort if it is a weight-equivalent dose).